Skin and Connective Tissue Diseases

All Conditions

Infections

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Rare Diseases

Dermatitis

Mycoses

Mycosis Fungoides

Psoriasis

Dermatitis, Atopic

Eczema

Skin Diseases

Alopecia

Alopecia Areata

Urticaria

Striae Distensae

Skin Diseases, Papulosquamous

Skin Diseases, Genetic

Genetic Diseases, Inborn

Skin Diseases, Eczematous

Hypersensitivity

Hypersensitivity, Immediate

Hypotrichosis

Hair Diseases

Pathological Conditions, Anatomical

Bacterial Infections

Communicable Diseases

Bacterial Infections and Mycoses

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Cutaneous

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Skin Diseases, Vascular

Skin Manifestations

Lymphosarcoma

UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2

UVB Irradiation maximum dose of 4000 mJ/cm2

The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.

UVA1 Irradiation

The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.

UVB Irradiation

John J Voorhees, MD

The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400nm) or shorter wavelength ultraviolet B \[UVB\] (290-320nm) irradiation in the treatment of inflammatory skin conditions (such as: atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, stretch marks and urticaria).

This research study aims to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific wavelength known as UVA1. This device has not been approved by the Food and Drug Administration (FDA) for general use in this country, as of yet, but it has been used quite successfully in Europe for several years in treating such conditions as scleroderma, atopic dermatitis, urticaria pigmentosa and other skin conditions.

Instead of UVA1 therapy, patients may receive ultraviolet radiation of a specific wavelength known as UVB. UVA1 light is a longer wavelength and therefore a lower energy wavelength than UVB. UVB light is often the light associated with getting a sunburn since it has a higher level of energy. UVB light has been used successfully in the treatment of many skin conditions.

The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400nm) or shorter wavelength UVB (290-320nm) irradiation in the treatment of inflammatory skin conditions. Inflammatory dermatoses refer to conditions like atopic dermatitis (eczema) and psoriasis in which circulating leukocytes (T cells, neutrophils, and monocytes) infiltrate the skin. The infiltrating cells may be of malignant phenotype as in mycosis fungoides (cutaneous T cell lymphoma-CTCL). Up to 50 patients with one of these diagnoses or related conditions will participate in this study. The affected areas on the body will be treated with UVA1 or UVB for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2. The maximum UVB dose will be 4000 mJ/cm2. This UVA1 dosing schedule has been safely used in Germany for treating patients with atopic dermatitis, mycosis fungoides, granuloma annulare, scleroderma, and urticaria pigmentosa. Subjects will be evaluated clinically at baseline, weeks 1, 2, 4, and then at monthly intervals. More frequent evaluation may be required depending on the condition being studied. Paired skin biopsies may be taken from involved and uninvolved (or treated and untreated) areas before and during UV therapy.

Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

The Effectiveness of UVA1 and UVB Irradiation in the Treatment of Inflammatory Dermatoses: An Open Pilot Study

University of Michigan

Assistant Professor of Dermatology, Medical School

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Asthma

Rhinitis

Papilloma

Virus Diseases

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.

Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed "atopic disease" (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.

Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded.

The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.

HPV test results

Gulsum Uysal

Cervical cancer is an important health problem in women. Human papillomavirus (HPV) is considered the primary etiological agent of cervical cancer worldwide. Cervical cancer screening methods are proved one of the few screening methods that are thought to decrease invasive cancer incidence and mortality. In our country, HPV screening is carried out free of charge by public health to women between the ages of 30-65 aim is to compare HPV screening results between women diagnosed with atopic disease and healthy women without a history of atopy.If HPV is detected more frequently in patients with atopy, it may be recommended to follow more closely in vaccination and screening programs. Therefore, our study was designed to evaluate whether HPV positivity is common in atopic women.

Patients between the ages of 30-65 with allergic complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed "atopic disease" (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Women aged between 30-65 years are scanned free of charge (HPV and smears) by the Public Health Institution in our country. The HPV results of the screened patients were noted retrospectively through the result reports of the patients, and those who were not screened were directed to Gynecology Department and HPV results were followed. Healthy women without allergic complaints applied for routine gynecologic examination occurred control group. Similarly, the HPV results of the control group were recorded.

Pregnant women, women who receive immunosuppressive therapy (including chemotherapy and chronic corticosteroid therapy), HIV positive women, women with cancer and performed hysterectomy were excluded. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.

Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded. Leukotriene receptor antagonists and histamine receptor antagonists were the main treatments for study group and all therapies were designed by the same clinician. Routine allergic skin tests were performed to all atopic patients during diagnosis.

Statistical analyses

Statistical Package for Social Sciences (SPSS) for Windows, version 18.0 (SPSS Inc., USA) was used to compare the clinical features of groups. Normality of data distribution was tested with Kolmogorov-Smirnov test. Data was shown as means ± standart deviation (SD) for continuous variables and the independent t test was used to assess the differences in variables between groups. Kruskal-Wallis, Mann-Whitney U-test and Bonferroni correction were used for values with non-normal distribution. P Values below 0.05 (p\<0.05) was accepted as statistically significant.

Atopic Diseases & Human Papilloma Virus

Comparison of Human Papilloma Virus Results in Women With and Without Atopic Disease

comparing HPV test results between groups.

Adana Numune Training and Research Hospital

Associate Professor in Obstetrics and Gynecology Department

Heart and Blood Diseases

Nutritional and Metabolic Diseases

Mastocytosis

Angioedema

Angioedemas, Hereditary

Mastocytosis, Systemic

Vascular Diseases

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Mast Cell Activation Disorders

Deficiency Diseases

Hereditary Complement Deficiency Diseases

Immunologic Deficiency Syndromes

Primary Immunodeficiency Diseases

Syndrome

Hereditary Angioedema

Systemic Mastocytosis

All Drugs and Chemicals

Complement C1 Inhibitor Protein

Angiotensin-Converting Enzyme Inhibitors

Broad definition: Angioedema due to urticaria (histaminergic/mast-cell) or non-urticarial (non-histaminergic) etiology Narrow definition: non-urticarial angioedema - distinguishing between C1-Inhibitor deficiency/dysfunction, and Angioedema with normal levels of C1-Inhibitor.

Broad definition: No medical history of angioedema of any kind, including urticaria (histaminergic) or drug-induced angioedema (e.g. ACE-Inhibitor angioedema)

Venipuncture

Henry Li, MD, PhD

Joseph Chiao, MD

Lili Wan, PhD

This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comprehensive assessment of patients experiencing recurrent angioedema attacks, including both urticarial and non-urticarial angioedema. The primary objective is to assess the efficiency of novel diagnostic assays, both individually and in combination, in comparison to currently available commercial tests. The ultimate goal is to establish the feasibility of developing an affordable and accurate laboratory test capable of diagnosing the diverse etiological manifestations of angioedema.

Purpose: The purpose of this prospective non-interventional non-randomized diagnostic study is to first identify patients with recurrent angioedema attacks, then collect their blood samples (venipuncture) and ultimately send the samples to specialized laboratories to perform multiple diagnostic assays, novel and traditional, that can distinguish the various forms of angioedema (urticaria and non-urticarial symptoms and signs), and healthy subjects.

Methods and Materials: Blood specimen collection from a total of 300 patients with recurrent angioedema attacks, and 300 healthy volunteers without a history of angioedema attacks. Laboratory testing will include assays on multiple platforms. Complement testing via immunoassay and biochemistry techniques. Flow Cytometry using multiple markers. Mass Spectrometry that includes bradykinin metabolite and histamine detection. Molecular Genetics include Sanger sequencing, Next Generation Sequencing (NGS), and digital PCR.

Patient population: Study participants to be screened who have a history of recurrent angioedema incidents as well as a population of healthy subjects. A medical history will be documented after obtaining informed patient consent to enter into the clinical trial. Each enrolled participant will have blood collected as whole blood, plasma and serum via venipuncture.

Eligibility criteria (inclusion) for sample collection (angioedema subject):

* Understand and sign the informed consent form before starting any study procedure.
* Adult or Child: aged 12 years of age or older (consent must be signed by a single parent or legal guardian).
* Angioedema symptoms and signs by medical history, or previous laboratory diagnostic testing, or genetically proven cases (e.g. SERPING1 or other mutation). Patients can be on active medication for the treatment and prophylaxis of angioedema. Angioedema cases must be verified by a clinician from IAA.
* Able to perform and endure safely the collection of peripheral blood samples (venipuncture), or optionally agree to have additional testing via a skin punch biopsy.

Eligibility criteria (inclusion) for sample collection (for healthy participant/subject):

* Understand and sign the informed consent form before starting any study procedure.
* Adult or Child: aged 12 years of age or older (consent must be signed by a single parent or legal guardian).
* No history of any angioedema symptoms and signs, previous laboratory diagnostic testing, or genetically proven cases.
* Able to perform and endure safely the collection of peripheral blood samples (venipuncture), or optionally agree to have additional testing via a skin punch biopsy.
* Not on ACE inhibitors and if on blood pressure medication, to indicate the drug(s).

Exclusion Criteria (for all participants):

* Minor: 11 years of age or younger.
* Cannot read or understand the informed consent form and instructions.
* Unable to perform the peripheral blood sample collection.
* Taking medications contraindicated for testing.
* History of excessive bleeding after phlebotomy, e.g. Hemophilia.
* Contraindication due to other health-related issues.

Angioedema Biomarker Research Study

The analyzed data will be published in a peer-reviewed journal and preliminary results published on clinicaltrials.gov website

Determining whether novel test methods can be more efficient than currently available or traditional laboratory test for angioedema diagnosis

Genetic testing that include know angioedema mutations, such as SERPING1

Mass Spectrometry analysis of plasma for bradykinin metabolites

development of novel immunoassay biomarkers, such as the detection of cleaved HMWK

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions	NCT00129415	Atopic Dermatit... Psoriasis Alopecia Mycosis Fungoid... Urticaria Dermatoses Stretch Marks	UVA1 Irradiatio... UVB Irradiation	10 Years - 80 Years	University of Michigan
Atopic Diseases & Human Papilloma Virus	NCT04397081	Human Papilloma... Atopic Asthma Atopic Disorder...	HPV test result...	30 Years - 65 Years	Adana Numune Training and Research Hospital
Atopic Diseases & Human Papilloma Virus	NCT04397081	Human Papilloma... Atopic Asthma Atopic Disorder...	HPV test result...	30 Years - 65 Years	Adana Numune Training and Research Hospital
Angioedema Biomarker Research Study	NCT06210698	Angioedema Angioedemas, He... Urticaria Mastocytosis ACE Inhibitor-I... C1 Inhibitor De... Systemic Mastoc... Indolent System...	Venipuncture	12 Years - 75 Years	Foundation For Rare Disease Research

Spots Global Cancer Trial Database for urticaria

Every month we try and update this database with for urticaria cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for urticaria

Every month we try and update this database with for urticaria cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for urticaria cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.